<DOC>
	<DOCNO>NCT02282137</DOCNO>
	<brief_summary>Single center , Prospective , Phase II expand access clinical study 68Ga-PSMA ( ProstaMedix TM ) use diagnosis management patient prostate cancer .</brief_summary>
	<brief_title>68Ga-PSMA PET-CT Scan Diagnosis Management Prostate Cancer</brief_title>
	<detailed_description>The goal trial evaluate patient suspected prostate cancer recurrence non-informative bone scintigraphy , computerize tomography ( CT ) magnetic resonance imaging ( MRI ) . 68Ga-PSMA PET/CT imaging may help identify potential site prostate cancer recurrence subsequent histologic confirmation . Suspected prostate recurrence base upon elevate blood prostate specific antigen ( PSA ) level follow initial therapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Signed informed consent . Male patient , age 18 year . Histologically and/or clinically confirm and/or suspicious Prostate cancer . Recent Blood test result 4.6 week follow : WBC : &gt; 2*109/L , Haemoglobin : &gt; 8.0g/Dl , Platelets : &gt; 50x109/L Known hypersensitivity 68Ga , HBEDCC , PSMA excipients 68GaPSMA . Current somatic psychiatric disease/condition may interfere objective assessment study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>